Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment
- 22 September 2017
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 31 (10) , 821-834
Abstract
Narcolepsy type 1 (NT1) is a rare sleep disorder caused by the very specific loss of hypothalamic hypocretin (Hcrt)/orexin neurons. The exact underlying process leading to this destruction is yet unknown, but indirect evidence strongly supports an autoimmune origin. The association with immune-related genetic factors, in particular the strongest association ever reported in a disease with an allele of a human leukocyte antigen (HLA) gene, and with environmental factors (i.e., the H1N1 influenza infection and vaccination during the pandemic in 2009) are in favor of such a hypothesis. The loss of Hcrt neurons is irreversible, and NT1 is currently an incurable and disabling condition. Patients are managed with symptomatic medication, targeting the main symptoms (excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep), and they require a lifelong treatment. Improved diagnostic tools, together with an increased understanding of the pathogenesis of NT1, may lead to new therapeutic and even preventive interventions. One future treatment could include Hcrt replacement, but this neuropeptide does not cross the blood–brain barrier. However, Hcrt receptor agonists may be promising candidates to treat NT1. Another option is immune-based therapies, administered at disease onset, with already some initiatives to slow down or stop the dysimmune process. Whether immune-based therapy could be beneficial in NT1 remains, however, to be proven.Keywords
This publication has 124 references indexed in Scilit:
- Genome Wide Analysis of Narcolepsy in China Implicates Novel Immune Loci and Reveals Changes in Association Prior to Versus After the 2009 H1N1 Influenza PandemicPLOS Genetics, 2013
- ImmunoChip Study Implicates Antigen Presentation to T Cells in NarcolepsyPLOS Genetics, 2013
- Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in FinlandPLOS ONE, 2012
- A Missense Mutation in Myelin Oligodendrocyte Glycoprotein as a Cause of Familial Narcolepsy with CataplexyThe American Journal of Human Genetics, 2011
- Low Vitamin D in Narcolepsy with CataplexyPLOS ONE, 2011
- Common variants in P2RY11 are associated with narcolepsyNature Genetics, 2010
- Increased Immune Complexes of Hypocretin Autoantibodies in NarcolepsyPLOS ONE, 2010
- Elevated Tribbles homolog 2–specific antibody levels in narcolepsy patientsJournal of Clinical Investigation, 2010
- Treating autoimmune disease by targeting CD8+T suppressor cellsExpert Opinion on Biological Therapy, 2009
- Narcolepsy is strongly associated with the T-cell receptor alpha locusNature Genetics, 2009